论文部分内容阅读
目的观察力达霉素(LDM)在体外、体内对肝癌的抑制作用。方法用四甲基偶氮唑蓝(MTT)方法测定力达霉素和丝裂霉素C对人肝癌BEL-7402细胞及小鼠肝癌22细胞的增生抑制作用。以小鼠移植性肝癌22模型观察不同剂量力达霉素的治疗效果。结果力达霉素和丝裂霉素对人肝癌BEL-7402细胞的半数抑制浓度(IC50)分别为(0.0030±0.0006)nmol/L和(150±27)nmol/L。力达霉素对小鼠肝癌22细胞的IC50为0.025nmol/L。体内试验:力达霉素静脉给药1次及延迟静脉给药3次对小鼠移植性肝癌22细胞的生长均有显著抑制作用。当通过静脉给予1次力达霉素剂量为0.025、0.05和0.1mg/kg时对肝癌22细胞抑瘤率分别为62%、72%和85%。结论力达霉素在体外对肝癌细胞增生有强烈的抑制作用,动物试验有显著疗效
Objective To observe the inhibitory effect of lidamycin (LDM) on liver cancer in vitro and in vivo. Methods MTT assay was used to determine the inhibitory effect of lidamycin and mitomycin C on proliferation of human hepatocellular carcinoma BEL-7402 cells and mouse hepatoma 22 cells. The therapeutic effect of different doses of lidamycin was observed in the mouse model of transplanted liver cancer22. Results The half inhibitory concentration (IC50) of lettomycin and mitomycin against human hepatocellular carcinoma BEL-7402 cells were (0.0030 ± 0.0006) nmol / L and (150 ± 27) nmol / L, respectively. Lidamycin on mouse hepatoma 22 cells IC50 0.025nmol / L. In vivo tests: Lidamycin administered once intravenously and delayed intravenous administration three times significantly inhibited the growth of transplanted hepatoma 22 cells in mice. The tumor inhibition rates of hepatoma 22 cells were 62%, 72%, and 85%, respectively, when the doses of lentomycin were intravenously administered at 0.025, 0.05 and 0.1 mg / kg. Conclusion Lidamycin has a strong inhibitory effect on the proliferation of hepatocellular carcinoma cells in vitro, and the animal experiment has a significant effect